Your browser doesn't support javascript.
loading
Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples.
Oueslati, Saoussen; Manai Bouokazi, Melek; Ramdhani, Ikrame; Escaut, Lélia; Pham, Tài; Ouzani, Souad; Anguel, Nadia; Bulifon, Sophie; Vauloup-Fellous, Christelle; Coilly, Audrey; Legros, Laurence; Guichardon, Magali; Fortineau, Nicolas; Dortet, Laurent; Roque-Afonso, Anne-Marie; Naas, Thierry.
Afiliação
  • Oueslati S; Bacteriology-Hygiene Unit, Hôpital Bicêtre, APHP Paris-Saclay, Team ReSIST, INSERM U1184, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France.
  • Manai Bouokazi M; Service de Virologie, Hôpital Paul-Brousse, APHP Paris-Saclay, and UMR 1193 Physiopathogénèse et Traitement des Maladies du Foie, 94800 Villejuif, France.
  • Ramdhani I; Unité de Recherche Clinique, Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France.
  • Escaut L; Service de Maladie Infectieuse et Tropicale, 94270 Le Kremlin-Bicêtre, France.
  • Pham T; Service de Médecine Intensive et Réanimation, Hôpital Bicêtre, APHP Paris-Saclay, 94270 Le Kremlin-Bicêtre, France.
  • Ouzani S; Bacteriology-Hygiene Unit, Hôpital Bicêtre, APHP Paris-Saclay, Team ReSIST, INSERM U1184, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France.
  • Anguel N; Service de Médecine Intensive et Réanimation, Hôpital Bicêtre, APHP Paris-Saclay, 94270 Le Kremlin-Bicêtre, France.
  • Bulifon S; Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, APHP Paris-Saclay, 94270 Le Kremlin-Bicêtre, France.
  • Vauloup-Fellous C; Service de Virologie, Hôpital Paul-Brousse, APHP Paris-Saclay, and UMR 1193 Physiopathogénèse et Traitement des Maladies du Foie, 94800 Villejuif, France.
  • Coilly A; Centre Hépatobiliaire, Hôpital Paul-Brousse, APHP Paris-Saclay, 94800 Villejuif, France.
  • Legros L; Hématologie Clinique, Hôpital Paul-Brousse, APHP Paris-Saclay, 94800 Villejuif, France.
  • Guichardon M; Gériatrie, Hôpital Paul-Brousse, APHP Paris-Saclay, 94800 Villejuif, France.
  • Fortineau N; Bacteriology-Hygiene Unit, Hôpital Bicêtre, APHP Paris-Saclay, Team ReSIST, INSERM U1184, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France.
  • Dortet L; Bacteriology-Hygiene Unit, Hôpital Bicêtre, APHP Paris-Saclay, Team ReSIST, INSERM U1184, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France.
  • Roque-Afonso AM; Service de Virologie, Hôpital Paul-Brousse, APHP Paris-Saclay, and UMR 1193 Physiopathogénèse et Traitement des Maladies du Foie, 94800 Villejuif, France.
  • Naas T; Bacteriology-Hygiene Unit, Hôpital Bicêtre, APHP Paris-Saclay, Team ReSIST, INSERM U1184, Université Paris-Saclay, LabEx LERMIT, 94270 Le Kremlin-Bicêtre, France.
Diagnostics (Basel) ; 12(10)2022 Oct 07.
Article em En | MEDLINE | ID: mdl-36292116
This study evaluated the performances of immunoassays (LFIA and ELISA) designed for SARS-CoV-2 Antigen (Ag)-detection in nasopharyngeal (NP) and serum samples in comparison to RT-PCR. NP samples from patients with respiratory symptoms (183 RT-PCR-positive and 74 RT-PCR-negative samples) were collected from March to April and November to December 2020. Seroconversion and antigen dynamics were assessed by symptom onset and day of RT-PCR diagnosis. Serum samples from 87 COVID-19 patients were used to investigate the added value of Ag quantification, at diagnosis and during follow-up. The sensitivity of COVID-VIRO-LFIA on samples with Ct ≤ 33, considered as the contagious threshold, was 86% on NPs (CI 95%: 79-90.5) and 76% on serum samples (CI 95%: 59.4-88), with a specificity of 100%. Serum N-Ag was detected during active infection as early as day two from symptom onset, with a diagnostic sensitivity of 81.5%. Within one week of symptom onset, diagnostic sensitivity and specificity reached 90.9% (95% CI, 85.1%-94.6%) and 98.3% (95% CI, 91.1%-99.9%), respectively. Serum N-Ag concentration closely correlated with disease severity. Longitudinal analysis revealed the simultaneous increase of antibodies and decrease of N-Ag. Sensitivities of COVID-VIRO-LFIA and COV-QUANTO-ELISA tests on NP and serum samples were close to 80%. They are suitable COVID-19-laboratory diagnostic tests, particularly when blood samples are available, thus reducing the requirement for NP sampling, and subsequent PCR analysis. ELISA titers may help to identify patients at risk of poor outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article